Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 5720  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (3,311 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Surgical Treatme...
 » Conclusion
 »  References
 »  Article Figures

 Article Access Statistics
    Viewed864    
    Printed16    
    Emailed0    
    PDF Downloaded20    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 7  |  Page : 219-227

Occipital Neuralgia: Advances in the Operative Management


Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA

Date of Submission18-Jan-2021
Date of Decision24-Jan-2021
Date of Acceptance29-Jan-2021
Date of Web Publication14-May-2021

Correspondence Address:
Dr. Bardia Amirlak
Department of Plastic Surgery, 1801 Inwood Rd., Dallas, TX - 75390
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.315980

Rights and Permissions

 » Abstract 


Background: Occipital neuralgia (ON) is a primary headache disorder characterized by sharp, shooting, or electric shock-like pain in the distribution of the greater, lesser, or third occipital nerves. Aim: To review the existing literature on the management of ON and to describe our technique of an endoscopic-assisted approach to decompress the GON proximally in areas of fibrous and muscular compression, as well as distally by thorough decompression of the occipital artery from the nerve. Methods: Relevant literature on the medical and surgical management of ON was reviewed. Literature on the anatomical relationships of occipital nerves and their clinical relevance were also reviewed. Results: While initial treatment of ON is conservative, peripheral nerve blocks and many surgical management approaches are available for patients with pain refractory to the medical treatment. These include greater occipital nerve blocks, occipital nerve stimulation, Botulinum toxin injections locally, pulsed radiofrequency ablation, cryoneuroablation, C-2 ganglionectomy, and endoscopic-assisted ON decompression. Conclusion: Patients of ON refractory to medical management can be benefitted by surgical approaches and occipital nerve blocks. Endoscopic-assisted ON decompression provides one such approach for the patients with vascular, fibrous or muscular compressions of occipital nerves resulting in intractable ON.


Keywords: Decompression surgeries, headache disorders, occipital neuralgia
Key Messages: This paper discusses medical, minimally invasive, and surgical treatments of occipital neuralgia. Additionally, the authors outline details of their endoscopic-assisted approach, intended for an extended decompression of the greater occipital nerve, combined with complete excision of the compressive occipital artery.


How to cite this article:
Wamsley CE, Chung M, Amirlak B. Occipital Neuralgia: Advances in the Operative Management. Neurol India 2021;69, Suppl S1:219-27

How to cite this URL:
Wamsley CE, Chung M, Amirlak B. Occipital Neuralgia: Advances in the Operative Management. Neurol India [serial online] 2021 [cited 2021 Jun 15];69, Suppl S1:219-27. Available from: https://www.neurologyindia.com/text.asp?2021/69/7/219/315980




Headache disorders, in particular migraine headaches and occipital neuralgia, have emerged as a major cause of morbidity worldwide. While there are currently no epidemiological studies documenting the worldwide prevalence or incidence of ON,[1] a small study of the Dutch population reported an estimated incidence of 3.2 cases per 100,000 individuals.[2] Further studies are therefore needed to confirm absolute data.

While occipital neuralgia and migraines with predominant occipital pain  are thought to be separate and distinct entities, there is often overlap in their presentation and consequently overlap in surgical treatment.[3],[4],[5],[6],[7] The majority of the publications on surgical decompression are on migraines, but most peripheral nerve surgeons understand that occipital neuralgia patients respond just as well if not better to surgery than patients with migraines with predominant occipital pain .[8] Evidence has identified at least four regions as trigger points for migraine headaches with potential surgical interventions. In the frontal and temporal regions, the irritation stems from the supraorbital/supratrochlear nerves, zygomaticotemporal branch of the trigeminal nerves, and auriculotemporal nerve[9] respectively. A third trigger site is related to turbinate and septal pathology.[3] The greater occipital nerve (GON) is involved in migraine of the occipital area, as well as possibly the accompanying lesser occipital nerve (LON).[7],[10] Occipital neuralgia (ON) is a distinct type of headache characterized by paroxysmal pain in the distribution of the greater, lesser, or third occipital nerves,[1] and has been described as a more peripheral irritation of the nerve rather than a central process like migraines. The pain may be caused by nerve injury, irritation, or compression by surrounding structures, such as the semispinalis capitis muscle, fibrous bands, and occipital artery.[3] While some cases are idiopathic, possible causes include trauma, compression (C1-C2-C3 osteoarthritis), or inflammation (rheumatoid polyarthritis or spondyloarthritis).[11],[12],[13] In this article, we shall review the medical and surgical management of ON and describe our approach to the surgical decompression of occipital neuralgia.

Medical management

Conservative management of ON is directed at alleviating secondary muscle tension and improving posture.[14] Anti-inflammatory medications and prescription muscle relaxants may reduce acute pain.[1] Other first-line drugs include the off-label use of antiepileptic medications, such as gabapentin, pregabalin, and carbamazepine, or antidepressants, such as amitriptyline.[11],[14] While these medications have been reported to reduce the frequency and severity of headaches, none have been systemically evaluated for the treatment of ON.[1],[14] Very little has been published in regards to oral steroids for the treatment of ON. One retrospective study of 43 patients, diagnosed with cluster headaches and not ON found that oral steroids compared to GON injections led to a greater incidence of partial response (82.7% vs 64.4%) and complete response (50.6% vs 35.6%) in patients diagnosed.[15] It is not uncommon for results to be unsatisfactory with medication alone, and patients may try multiple regimens in search of pain relief,[11] eventually requiring more invasive treatments.

Anatomical considerations

In order to understand the management of ON, the pertinent anatomy must be discussed. The GON originates from the medial branch of the dorsal ramus of the C2 spinal nerve. It emerges under the obliquus capitis inferior muscle and moves cephalically to the suboccipital triangle.[11] It then pierces the semispinalis capitis muscle and runs rostrolateral deep to the trapezius muscle.[1],[16] It pierces the trapezius aponeurosis slightly inferior to the nuchal ridge, where it enters the subcutaneous layer and lies medial to the occipital artery.[3] The GON provides sensory innervation to a large portion of the posterior scalp up to the vertex.[17] The lesser occipital nerve (LON) originates from the lateral branch of C2 and sometimes C3 in the cervical plexus. It travels along the posterior border of the sternocleidomastoid muscle and provides sensation to the inferior occiput.[1] It also innervates the lateral scalp posterior and superior to the ear.[11],[17],[18] Finally, the third occipital nerve is a branch of the posterior ramus of the C2 spinal nerve.[11] It emerges from the semispinalis capitis and trapezius muscles to innervate the upper neck and lower occipital scalp [Figure 1].[1],[17],[19]
Figure 1: The 6 Compression Points of the Greater Occipital Nerve. (1) The deepest, most proximal point is between the semispinalis and obliquus capitis inferior, close to the spinous process. (2) The entrance into the semispinalis capitis muscle. (3) The nerve's exit from the semispinalis capitis. (4) The entrance of the nerve into the trapezius muscle. (5) Where the nerve exits the trapezius fascia insertion into the nuchal line. Between points 4 and 5 there is continuous compression of the nerve by the trapezius fascia. (6) The occipital artery may also dynamically compress of the GON at four levels

Click here to view


Occipital nerve blockade

Included in the International Headache Society diagnostic criteria of ON is pain that is temporarily eased by local anesthetic injection to the affected nerve.[20] Besides aiding in diagnosis, the temporary relief provided by these anesthetic blocks or steroid injections makes them a high-yield intervention to alleviate pain associated with ON.[1] The effects of a GON block are thought to be due to diminished afferent input to the second-order trigeminal nucleus caudalis neurons, which receive input from the occipital and trigeminal afferents, leading to decreased central sensitization if there is a migraine component to the headache.[21],[22]

Anesthetic blocks can be guided using anatomical landmarks or imaging modalities, such as fluoroscopy and ultrasound.[11] According to an expert consensus published by the American Headache Society, the recommended site of injection for a GON block is one-third of the way from the external occipital protuberance to the mastoid process.[21],[23] The expert consensus also recommended for a LON block, the injection should be two-thirds of the way from the external occipital protuberance to the mastoid.[23] Our experience in peripheral nerve surgery is more concise. The GON is one to two centimeters from the midline and three centimeters inferior to the occipital protuberance and deep to the trapezius fascia. The exact area to block is then guided by the patient's tenderness while sitting in a neck flexed position.[3] The LON emerges from the posterior border of the sternocleidomastoid. The area of tenderness is palpated, with the muscle at an average of six centimeters lateral to the y-axis and seven centimeters caudal to the x-axis. (The y-axis is the vertical midline in the posterior scalp through the midline of the cervical spine. The x-axis is a horizontal line drawn between the most anterosuperior points of the external auditory meatus.) [Figure 1]. The injection in this area is less deep than the GON.[24] The third occipital nerve is not routinely injected, as it is not often involved in headache pathology.[25]

The most widely used nerve blocks are lidocaine and bupivacaine, which can be combined in an attempt to achieve a rapid onset of nerve blockade and a longer duration of action due to the presence of bupivacaine.[1],[21] The AHS expert consensus recommends using 1-2% lidocaine and/or 0.25-0.5% bupivacaine.[21] If a combination is used, the recommended volume ratio of lidocaine to bupivacaine is 1:1-1:3.[21] Corticosteroids have frequently been used in combination with anesthetic nerve blocks, most commonly 40 mg triamcinolone or 40-80 mg methylprednisone.[21] There are currently no studies confirming the addition of a corticosteroid increases the efficacy or duration of pain relief in patients with ON.[1] The evidence to support the use of corticosteroids with local anesthetic appears to be strongest for cluster headaches, though further investigation is necessary.[26]

While several studies have shown the benefits of anesthetic nerve blockade, effects of these treatments, however, are often short-lived and repeat injections may be required.[11] While Kuhn et al. reported a minimum of 80% pain relief in ten subjects treated with infiltration of the GON with 0.5% bupivacaine followed by a corticosteroid, the benefits lasted from one week to four months.[27]

Onabotulinum Toxin Type A The Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trial prompted FDA approval of Onabotulinum Toxin Type A for the treatment of chronic migraines in 2010.[11],[28],[29] Onabotulinum Toxin Type A main mechanism of action is inhibition of acetylcholine neurotransmitter release at presynaptic nerve terminals.[30] Research suggests the inhibition of neurotransmitter release from nociceptive nerve terminals may lend to a possible analgesic effect.[31] Additionally, it is thought that Onabotulinum Toxin Type A may inhibit the release of inflammatory mediators from sensory nerves.[28]

According to the American Academy of Neurology guidelines, there is level U (insufficient) evidence for established efficacy of this neurotoxin for the treatment of ON.[11],[32] In reviewing the literature, only two published studies were found evaluating Onabotulinum Toxin Type A specifically as a treatment for ON. Kapural et al. treated six patients with severe intractable ON with 50 U of Onabotulinum Toxin Type A (100 U for bilateral pain). Significant decreases in the pain Visual Analog Scale and improvements in the Pain Disability index were noted in five of the six patients four weeks post-treatment. The duration of pain relief was, on average, 16 weeks.[33] Taylor et al. published a subsequent study with six patients. 12 weeks post-treatment, there was an improvement in sharp, shooting pain and quality of life measurements, but no statistically significant improvement was noted in the dull, aching pain or pins-and-needles-type pain. Additionally, there was no reduction in pain medication usage.[1],[34] As no randomized, blinded clinical trials have been conducted, definitive conclusions cannot yet be drawn from these preliminary data.[32],[35] The senior author (BA) uses Onabotulinum Toxin Type A for treatment of ON using the ART technique, which delivers the Onabotulinum Toxin Type A in a more targeted fashion around the occipital nerves.[36]

Pulsed Radiofrequency Ablation (PFRA)

PFRA has been proposed as a minimally invasive treatment for ON, although evidence confirming its long-term effects is lacking.[37] The pulsed method was developed as an alternative to continuous radiofrequency lesioning, which has been used to treat various neuralgias but carries a potential risk of post-operative deafferentation pain.[38] PFRA exposes the nerve to a series of short-duration, high voltage pulses.[1],[14],[39] Although the exact mechanism by which PFRA exerts its analgesic effect is unknown, it is theorized that this technique decreases pain by inducing a low-intensity electrical field around sensory nerves, inhibiting long-term potentiation in unmyelinated C fibers and lightly myelinated A-delta fibers, without the thermal coagulation seen with continuous radiofrequency ablation.[11],[37],[40] The electrical field also induces a transmembrane potential that can have significant effects on affected cells, including tissue disruption, ion channel disruption, and threshold potential alterations.[11],[40]

Studies have demonstrated short to intermediate pain relief in patients with ON using PFRA.[37] Vanelderen et al. conducted a prospective analysis of 19 patients with ON. 68.4%, 57.9%, and 52.6% of patients reported a pain improvement of at least 50% one, two, and six months post-treatment.[14] Additionally, the median Medication Quantification Scale score declined six months post-treatment. No complications were reported, though the authors argued these results warrant further placebo-controlled studies.[41] Huang et al. also collected retrospective data on 102 patients who underwent PFRA. It is the largest study to date evaluating the effects of this treatment on ON. 51% of patients experienced at least 50% pain relief lasting at least three months. Factors associated with positive outcomes included a traumatic inciting event, lower diagnostic nerve block volumes, and multiple rounds of PFRA.[37] Finally, Cohen et al. performed a randomized, double-blind study comparing PFRA to steroid injections for ON. The authors found that PFRA resulted in a greater reduction in occipital pain at six weeks compared to steroid injections. Worst occipital pain for the patients treated with PFRA was also improved at three months, but the extent of pain relief diminished by six months.[42]

Cryoneuroablation (CA)

CA is a technique that may be used to treat ON in cases where nerve blocks or steroid injections have failed.[43] This interventional modality involves the application of a cryoprobe to tissues, creating a drastic temperature decrease and resultant conduction block.[44] The extremely low temperature allows ice crystals to form around the nerve, causing vascular damage to the vasa nervorum, resulting in endoneural edema.[44],[45] Disrupting the nerve structure leads to  Wallerian degeneration More Details while leaving the myelin sheath and endoneurium intact.[45],[46] It is proposed that the blocked nerve conduction of afferent and efferent pain pathways may alleviate or eliminate neuropathic pain.[44] Furthermore, it has been proposed that the efficacy of CA is proportional to the degree of cold temperature achieved and the length of exposure to that temperature.[46]

Traditional CA was performed using landmark guidance and by palpating for the point of maximum tenderness.[44] In a retrospective study evaluating this method, Kim et al. found that among 38 patients treated with CA, the average improvement in pain relief was 57.9%, with a mean duration of 6.1 months, compared to 71.2% pain improvement in patients who received a local anesthetic injection. Two patients reported post-procedural neuritis and one patient was monitored for a procedure-related hematoma.[44]

While cryoneurolysis in the traditional procedure was performed at the nuchal ridge, the GON in this region has been found to show large anatomical variation and can be located anywhere between 0.5 and 7.5 centimetres from the midline.[43],[47] Newer methods using imaging guidance have implemented a more proximal injection approach, superficial to the obliquus capitis inferior muscle.[43],[48],[49] Kastler et al. reported that with this CT-guided method, five of seven patients had at least 50% improvement in pain three months post-treatment.[49] Mean intra-procedural pain was less than five out of ten. A limited number of studies, including those with small sample size and brief follow-up period, do not yet allow for definitive conclusions about the technique to be drawn.


 » Surgical Treatments for Occipital Neuralgia Top


Nerve stimulation

Occipital nerve stimulation is a minimally invasive, adjustable, and reversible technique first described by Picaza et al. in 1977.[50] The implantable device consists of a subcutaneous regional electrode and pulse generator.[51] It is proposed that stimulation of the distal branches of C2 and C3, and the peripheral extension of the trigeminocervical complex may inhibit central nociceptive impulses.[52] The Neuromodulation Appropriateness Consensus Committee concluded that nerve stimulation for ON is recommendable in cases refractory to conservative medical treatment.[53] Treatment is considered successful if there is a greater than 50% reduction in pain, decrease in the number of headache days, or patient-reported improvement in the quality of life.[51]

Implantation can be performed after a trial period using local anesthetic and conscious sedation or general anesthesia.[53] There are two accepted approaches to implantation. In the lateral approach, an incision is made along the mastoid process and the stimulating lead is subcutaneously advanced towards the midline at the level of C1.[15] In the medial approach, a 2 centimeters midline incision is made at the level of C1, and the leads are inserted laterally from that midpoint.[51] The pulse generator can be placed in the upper buttock, abdomen, infrascapular region, or infraclavicular region.[54] The most common complication is lead migration, with a reported incidence varying from a few percent to as high as 100%.[55],[56] Other adverse events include occipital muscle spasms, due to the lead being placed too deeply, lead fracture, infection, skin erosion, and localized pain at the implant sites.[51],[53],[57]

PET scans have shown that in chronic migraine patients treated with occipital nerve stimulation, there is increased cerebral blood flow in the treated areas involved in central neuromodulation.[53],[58] The Occipital Nerve Stimulation for the Treatment of Intractable Migraine (ONSTIM) trial was a multicenter, prospective study that randomized patients who responded favorably to occipital nerve block into three groups: adjustable nerve stimulation, preset nerve stimulation, or medical management. Three months post-treatment, the percent reduction in headache days per month was 27.0%, 8.8%, and 4.4% for the groups, respectively.[18] A study by Salmasi et al. found that after eight months post-treatment, average pain was reduced by 50%. One patient developed an adverse reaction to the adhesive of the battery transmitter, but it was not severe enough to discontinue treatment.[59] Finally, Raoul et al. reported that in 60 patients with intractable occipital headaches, 76% had a least a 50% decrease in their pain scores. However, the authors argued that the high frequency of complications must be considered in the surgical decision.[13]

C-2 ganglionectomy

An older technique not routinely performed is microsurgical C-2 ganglionectomy. Because the C2 ganglion and nerve root lie outside the spinal canal, between the arch of C1 and lamina of C2, C2 sensory neurons and axons may be vulnerable to injury or compression.[60],[61],[62] Dorsal root ganglionectomy removes the primary sensory neuronal cell bodies, and there is no possibility of axonal regeneration.[61] Lozano et al. performed C2 ganglionectomies on 39 patients with intractable occipital pain and found that 19 patients experienced a greater than 90% reduction in pain, while 13 patients experienced treatment failure. Patients with post-traumatic pain reported the most favorable responses. Post-operatively, one patient developed numbness as a result of deafferentation syndrome.[61] Another study by Acar et al. noted that the benefits of C2 ganglionectomy were short-lived, with the average pain relief duration lasting 12 months.[63] Due to limited evidence in favor of this procedure and support of other treatment options, C2 ganglionectomies are not commonly performed for the treatment of ON.

Screening patients for surgery

In order to identify candidates for surgery, patients must undergo a thorough screening process. Gfrerer et al. discuss one such strategy, summarized below.[64]

  1. Pain point: Patients are asked to point to where the pain starts with one finger. For ON related to irritation of the GON, pain usually begins at the exit point of the nerve from the semispinalis muscle, 3 centimeters caudal to the occipital protuberance and 1.5-2 centimeters lateral to the midline.[64] Gfrerer et al. report that pain related to the LON is much more variable, but is usually more lateral than GON pain and tracks from mid-neck into the mastoid groove and then lateral to the ear.[64]
  2. Appropriate symptoms: Certain triggers generally result in a characteristic set of symptoms. For ON due to GON irritation, pain can radiate to other areas, such as the temple or behind the eye, and has to be differentiated from others areas of irritation. Neck muscles may be tight. Pain is usually triggered by stress, exercise, or heavy lifting and is alleviated by heated compresses.[1] LON pain, on the other hand, can result in a more lateral pain and often radiates closer to the ear.[64]
  3. Neurologist diagnosis: It is critical for patients to receive an official diagnosis of ON or migraine from a neurologist before surgery may be considered. This documented diagnosis can be made using the International Classification of Headache Disorders criteria, and other causes of headache, such as intracranial pathology or spinal disease, must be ruled out.[20],[65]
  4. Mental health screening: Preoperative mental health is of utmost importance, and must be part of the surgical planning discussion. Additionally, narcotic use prior to surgery must be eliminated, as it may significantly lower the surgical response.


The authors' approach to surgical decompression/deactivation of occipital neuralgia

The GON can be decompressed using an endoscopic-assisted approach and counter incision, while the LON may be decompressed or avulsed, depending on the size of the nerve. Both procedures are outlined below.

Prior to surgery, preoperative markings should be made with the patient in a relaxed, seated position. The GON is generally found 1.5 cm lateral to the midline and 3 cm below the occipital protuberance.[66] However, this varies and should be confirmed with palpation of the tender area before surgery. The LON is 7 cm lateral to the midline and 6 cm inferior to the external auditory canal.[66] As the point of maximum tenderness may not always correlate to these measurements, these areas should also be marked bilaterally.

Greater occipital nerve decompression

There are six identified compression points of the GON that should be addressed for complete decompression [Figure 1].[3],[64],[67],[68] We also have added several distal vascular dynamic compression points that need to be addressed, and the addition of an endoscope helps with visualization of these areas. The six points of compression are:

  1. The deepest, most proximal point is between the semispinalis and the obliquus capitis inferior, with a diffuse fascial compression over the nerve. This is close to the spinous process.
  2. The entrance into the semispinalis capitis muscle.
  3. The nerve's exit from the semispinalis capitis muscle, which is covered with a thin layer of fascia.
  4. The entrance of the nerve into the trapezius muscle.
  5. Where the nerve exits the trapezius fascia insertion into the nuchal line. Between points 4 and 5 there is continuous compression of the nerve by the trapezius fascia.
  6. Any interaction with the occipital artery.


There is a close relationship between the GON and OA that has not previously been reported[69]; in particular, there are four compression sites between the GON and OA distally, after the nerve exits the trapezius fascia. This pattern appears to be consistent, as illustrated in [Figure 1]. (A) The OA first approaches lateral to medial and dives under the GON. (B) It then loops from medial to lateral over the GON. (C) The OA then intertwines with the medial branch of the GON. (D) Finally, the OA travels parallel medial branch of the nerve bifurcation at its most distal part. The endoscopic-assisted approach with a counter incision, described below, allows for better visualization of this relationship in order to completely decompress the GON from the OA.[69]

The patient is placed on the operating table in the prone position with shoulders taped back [Figure 2]. After injecting lidocaine with epinephrine, a 3-4 cm midline incision is made just below the occipital protuberance [Figure 3].[36] Electrocautery is then used to further open the midline. Underneath the trapezius fascia is the trapezius muscle, whose fibers run lateral and oblique to the midline raphe.[64] The third occipital nerve is often encountered here and can be avulsed using hemostat-assisted traction neurectomy [Figure 4]. In a retrospective study of 229 patients, removal of the third occipital nerve did not alter post-operative results and its removal is therefore appropriate if dissection is difficult.[25]
Figure 2: After induction of general anesthesia, the patient is flipped into the prone position. All areas of the bed must be padded to prevent pressure ulcers. A pillow with a mirror allows visualization of the endotracheal tube and confirms correct positioning of the face. The shoulders are taped back to provide better access to the GON and LON incisions

Click here to view
Figure 3: This image shows key locations of several structures. The emergence of the GON and distal compression points with the occipital artery (red) are marked with a black “X”, usually corresponding to points of maximal tenderness. The midline and course of the LON are also outlined, more laterally. The proximal tender area of the LON, as well as the distal area in the mastoid groove are marked with a blue “X.”

Click here to view
Figure 4: During dissection down the midline, the third occipital nerve may be encountered. This nerve can be avulsed using hemostat-assisted traction neurectomy. To avoid confusing a large third occipital nerve with the GON, it is important to pay attention to its depth in relation to the trapezius fascia and semispinalis capitis muscle

Click here to view


Deeper dissection leads to the identification of the semispinalis capitis muscle, whose fibers run vertically [Figure 5].[66] The GON can be identified through blunt dissection laterally between the top surface of the semispinalis capitis and underneath the trapezius fascia [Figure 6].[66] A 1 x 1 cm block of the medial semispinalis muscle is excised to prevent future nerve compression.[69] The GON is then decompressed proximally with the full release of the obliquus fascia.
Figure 5: The trapezius and semispinalis capitis muscles must be differentiated from each other. Oftern, there is a midline extension of the trapezius muscle. Lateral to the midline raphe, the oblique fibers of the trapezius muscle are encountered first, followed by a layer of fascia underneath. The semispinalis muscle is deep to the trapezius and can be identified by its vertical fibers, lighter color, and bulkier appearance compared to the trapezius muscle

Click here to view
Figure 6: The GON can be identified through blunt dissection laterally between the top surface of the semispinalis capitis and underneath the trapezius fascia. Following identification, a vessel loop is used to provide gentle traction on the nerve. A 1 x 1 cm block of the semispinalis muscle medial to the emergence of the GON is excised. The image above illustrates nerve release after excision

Click here to view


Decompression of GON continues by releasing the trapezius tunnel under direct visualization. At this point, the GON must be released from the OA.

The most common approach to decompression of the GON involves limited dissection, manipulation, and cauterization of the OA, as described by Chmielewski et al.[6] However, due to the intimate relationship between the GON and OA, as described above, a counter incision is necessary to completely and safely address the entire segment of the artery compressing the GON. An endoscope assists in detailed visualization of vessels at the proximal points of dynamic compression that otherwise may be missed by the naked eye. The counter incision marking is made obliquely and laterally above the ear following the path of the GON [Figure 7].[66] Electrocautery is performed to dissect down to the nerve. However, once the nerve is visible, blunt dissection must be performed to avoid GON injury. Dissection continues until both the GON and OA are identified. A 30-degree high-definition endoscope is inserted through the midline incision to better visualize the pulsating artery proximally [Figure 8].[69] The artery is dissected off the nerve carefully, and the artery is destroyed with cautery to prevent backflow.
Figure 7: Following traditional decompression of the trapezius tunnel, a 2 cm counter incision is made in the area of the GON tail. The nerve must be separated from the occipital artery, which is usually wrapped around the medial distal branch of the GON at this point

Click here to view
Figure 8: (a) A 30-degree high-definition endoscope is inserted through the midline incision to visualize potential GON compression points at the proximal end of the occipital artery. (b) An example of an endoscopic view of the greater occipital nerve after the occipital artery is dissected off and cauterized

Click here to view


To provide padding and prevent any muscle or fibrous reconstitution around the decompressed GON, a subcutaneous flap of adipose tissue is taken caudally, passed under the GON, and sutured to the midline raphe to wrap and protect the nerve. In patients with a very low BMI and inadequate amount of fat, a nerve protector may instead be used.[66]

Lesser occipital nerve decompression/traction neurectomy

The LON lies at the posterior border of the sternocleidomastoid muscle [Figure 1] and [Figure 9]a. This nerve can be addressed through decompression or traction neurectomy.
Figure 9: (a) The LON lies at that the posterior border of the sternocleidomastoid muscle. The path of the nerve (green), prior to any incisions being made. The proximal and distal areas of tenderness are marked with an “X.” It is important that the surgeon give themselves adequate exposure to identify the sternocleidomastoid muscle. (b) Larger nerves should be decompressed, while smaller nerves can be removed using traction neurectomy. Prior to avulsion, a nerve stimulator should be used to confirm avoidance of the spinal accessory nerve

Click here to view


Larger nerves should be decompressed, as any nerve avulsion may have some morbidity. To decompress the LON, adequate exposure is necessary to identify the sternocleidomastoid muscle.[66] The patient is not paralyzed in order to ensure minimal injury to the spinal accessory nerve. The senior author (BA) conducted a study on six cadavers analyzing the anatomical relationship between the lesser occipital nerve, greater auricular nerve, and spinal accessory nerve (SAN) in the posterior triangle of the neck. While there is variable anatomy in this area, the LON is always found caudal to the emergence of the SAN, emerging from a deeper plane behind the sternocleidomastoid muscle.[19] The danger zone during dissection, the point of LON and SAN decussation is often very close to the point of emergence of the LON and at times maybe indistinguishable from the emergence of the SAN.[9] Surgeons approaching the posterior triangle must use caution, especially when using visually limited incisions, blunt dissection, or electrocautery.[19]

After dissection down to the LON, if the nerve is noted to be of smaller caliber, it can be avulsed [Figure 9]b. In a randomized prospective study conducted by Guyuron et al., traction neurectomy (avulsion) was found to have equal results when compared to cutting, crushing, and burying.[5] Prior to avulsion, a nerve stimulator should be used to confirm avoidance of the SAN.

Post-operative care, residual pain, and refractory cases

Post-operative drain removal happens between days two and four. Generally, this operation has minimal morbidity and few complications. Nerve irritation, paresthesia, and hyperesthesia can happen after surgery and usually subsides on their own. Neurontin (gabapentin) and Lyrican (pregabalin) can help with this, as well as a frequent scalp massage. Gentle range of motion physical therapy (ROM PT) will also ease any stiffness.

In circumstances of residual pain, patients have the option of Anatomical Regional Targeted Botulinum Toxin (ART-BOTOX). This method, developed by the senior author (BA), focuses on three components: “Anatomical,” based on the anatomical location of nerves known to be causing pain; “Regional,” focusing on areas where pain begins; and “Targeted,” based on the surface topography of the tender area, which may not fully correlate with the expected location due to anatomical variations.[36] This focused delivery is based on the theory that Onabotulinum Toxin Type A may work directly on the nerve to decrease pain, rather than acting indirectly on the muscle alone.[36],[70] The ART technique can be used in other areas in instances of pain shifting from the occipital area to the forehead or temples, which could happen in cases of mixed migraine and ON.

For patients with ON, the area of maximum tenderness tends to be 0.5-1 centimeters lateral to the exit point of the GON from the semispinalis capitis muscle, likely due to irritation and compression by the nuchal line and greater occipital vessels.[36] There may be another point of tenderness in the distal ends of the GON or LON as they course over the mastoid and superior areas of the ear, where they intertwine with the OA [Figure 10].[36]
Figure 10: Occipital Injection Sites, reprinted with permission. The occipital protuberance (black triangle) is used as a landmark to identify the GON. The GON (black ovals), GON tail (black squares), LON (gray ovals), and LON tails (gray squares) are shown in this image. The third occipital nerve (white circles) is not routinely injected, as it is not often involved in headache pathology

Click here to view


In cases of ON that continue to be refractory despite thorough decompression of the GON, a surgical option is GON excision as described by Ducic et al. During this procedure, a previously decompressed GON can be transected, with excision of the dorsal portion and burial of the proximal end into the nuchal musculature. A retrospective review of 71 patients who underwent GON excision after decompression found that 70.4% experienced at least a 50% reduction in migraine index score. The most common adverse events were numbness or hypersensitivity in the denervated area, occurring in up to 31% of patients.[71]


 » Conclusion Top


Occipital neuralgia is a primary headache disorder characterized by sharp, shooting, or electric shock-like pain in the distribution of the occipital nerve. While initial treatment is conservative, surgical management has emerged as a means of addressing refractory pain. The authors have outlined details of an endoscopic-assisted approach to decompress the GON proximally in areas of fibrous and muscular compression, as well as distally by thorough decompression of the occipital artery from the nerve, which is not the gold standard surgical treatment of occipital neuralgia.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Dougherty C. Occipital neuralgia. Curr Pain Headache Rep 2014;18:411. doi: 10.1007/s11916-014-0411-x.  Back to cited text no. 1
    
2.
Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147:122-7.  Back to cited text no. 2
    
3.
Mosser SW, Guyuron B, Janis JE, Rohrich RJ. The anatomy of the greater occipital nerve: Implications for the etiology of migraine headaches. Plast Reconstr Surg 2004;113:693-7; discussion 8-700.  Back to cited text no. 3
    
4.
Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 2005;115:1-9.  Back to cited text no. 4
    
5.
Guyuron B, Harvey D, Reed D. A prospective randomized outcomes comparison of two temple migraine trigger site deactivation techniques. Plast Reconstr Surg 2015;136:159-65.  Back to cited text no. 5
    
6.
Chmielewski L, Liu MT, Guyuron B. The role of occipital artery resection in the surgical treatment of occipital migraine headaches. Plast Reconstr Surg 2013;131:351e-6e.  Back to cited text no. 6
    
7.
Ducic I, Hartmann EC, Larson EE. Indications and outcomes for surgical treatment of patients with chronic migraine headaches caused by occipital neuralgia. Plast Reconstr Surg 2009;123:1453-61.  Back to cited text no. 7
    
8.
Blake P, Nir RR, Perry CJ, Burstein R. Tracking patients with chronic occipital headache after occipital nerve decompression surgery: A case series. Cephalalgia 2019;39:556-63.  Back to cited text no. 8
    
9.
Sanniec K, Borsting E, Amirlak B. Decompression-avulsion of the auriculotemporal nerve for treatment of migraines and chronic headaches. Plast Reconstr Surg Glob Open 2016;4:e678.  Back to cited text no. 9
    
10.
Ipekdal HI, Yiğitoğlu PH, Eker A, Ozmenoğlu M. Occipital neuralgia as an unusual manifestation of herpes zoster infection of the lesser occipital nerve: A case report. Acta Neurol Belg 2013;113:201-2.  Back to cited text no. 10
    
11.
Antony AB, Mazzola AJ, Dhaliwal GS, Hunter CW. Neurostimulation for the treatment of chronic head and facial pain: A literature review. Pain Physician 2019;22:447-77.  Back to cited text no. 11
    
12.
Tancredi A, Caputi F. Greater occipital neuralgia and arthrosis of C1-2 lateral joint. Eur J Neurol 2004;11:573-4.  Back to cited text no. 12
    
13.
Raoul S, Nguyen JM, Kuhn E, de Chauvigny E, Lejczak S, Nguyen JP, et al. Efficacy of occipital nerve stimulation to treat refractory occipital headaches: A single-institution study of 60 patients. Neuromodulation 2020;23:789-95.  Back to cited text no. 13
    
14.
Vanelderen P, Lataster A, Levy R, Mekhail N, van Kleef M, Van Zundert J. 8. Occipital neuralgia. Pain Pract 2010;10:137-44.  Back to cited text no. 14
    
15.
Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999;2:217-21.  Back to cited text no. 15
    
16.
Güvençer M, Akyer P, Sayhan S, Tetik S. The importance of the greater occipital nerve in the occipital and the suboccipital region for nerve blockade and surgical approaches--An anatomic study on cadavers. Clin Neurol Neurosurg 2011;113:289-94.  Back to cited text no. 16
    
17.
Drake R, Vogl AW, Mitchell AW. Gray's Anatomy for Students E-Book. Elsevier Health Sciences; 2009.  Back to cited text no. 17
    
18.
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31:271-85.  Back to cited text no. 18
    
19.
Amirlak B, Lu KB, Erickson CR, Sanniec K, Totonchi A, Peled ZM, et al. In-depth look at the anatomical relationship of the lesser occipital nerve, great auricular nerve, and spinal accessory nerve and their implication in safety of operations in the posterior triangle of the neck. Plast Reconstr Surg 2020;146:509-14.  Back to cited text no. 19
    
20.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, (beta version). Cephalalgia 2013;33:629-808.  Back to cited text no. 20
    
21.
Blumenfeld A, Ashkenazi A, Evans RW. Occipital and trigeminal nerve blocks for migraine. Headache 2015;55:682-9.  Back to cited text no. 21
    
22.
Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 1997;73:23-8.  Back to cited text no. 22
    
23.
Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--A narrative review. Headache 2013;53:437-46.  Back to cited text no. 23
    
24.
Lee M, Brown M, Chepla K, Okada H, Gatherwright J, Totonchi A, et al. An anatomical study of the lesser occipital nerve and its potential compression points: Implications for surgical treatment of migraine headaches. Plast Reconstr Surg 2013;132:1551-6.  Back to cited text no. 24
    
25.
Lee M, Lineberry K, Reed D, Guyuron B. The role of the third occipital nerve in surgical treatment of occipital migraine headaches. J Plast Reconstr Aesthet Surg 2013;66:1335-9.  Back to cited text no. 25
    
26.
Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, et al. Peripheral nerve blocks and trigger point injections in headache management-A systematic review and suggestions for future research. Headache 2010;50:943-52.  Back to cited text no. 26
    
27.
Kuhn WF, Kuhn SC, Gilberstadt H. Occipital neuralgias: Clinical recognition of a complicated headache. A case series and literature review. J Orofac Pain 1997;11:158-65.  Back to cited text no. 27
    
28.
Oh HM, Chung ME. Botulinum toxin for neuropathic pain: A review of the literature. Toxins (Basel) 2015;7:3127-54.  Back to cited text no. 28
    
29.
Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.  Back to cited text no. 29
    
30.
Senno R, Schonfeld E, Nagar C. OnabotulinumtoxinA injections: Treatment of reversible cerebral vasoconstriction syndrome chronic daily headaches. BMJ Case Rep 2019;12:e228562. doi: 10.1136/bcr-2018-228562.  Back to cited text no. 30
    
31.
Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache 2003;43(Suppl 1):S25-33.  Back to cited text no. 31
    
32.
Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: An overview. Pain Manag 2014;4:129-51.  Back to cited text no. 32
    
33.
Kapural L, Stillman M, Kapural M, McIntyre P, Guirgius M, Mekhail N. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: A case series. Pain Pract 2007;7:337-40.  Back to cited text no. 33
    
34.
Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: A pilot study. Headache 2008;48:1476-81.  Back to cited text no. 34
    
35.
Mittal SO, Safarpour D, Jabbari B. Botulinum Toxin Treatment of neuropathic pain. Semin Neurol 2016;36:73-83.  Back to cited text no. 35
    
36.
Amirlak B, Sanniec K, Pezeshk R, Chung M. Anatomical regional targeted (ART) BOTOX injection technique: A novel paradigm for migraines and chronic headaches. Plast Reconstr Surg Glob Open 2016;4:e1194.  Back to cited text no. 36
    
37.
Huang JH, Galvagno SM Jr, Hameed M, Wilkinson I, Erdek MA, Patel A, et al. Occipital nerve pulsed radiofrequency treatment: A multi-center study evaluating predictors of outcome. Pain Med 2012;13:489-97.  Back to cited text no. 37
    
38.
Navani A, Mahajan G, Kreis P, Fishman SM. A case of pulsed radiofrequency lesioning for occipital neuralgia. Pain Med 2006;7:453-6.  Back to cited text no. 38
    
39.
Sluijter M. Radiofrequency, Part 2. Meggen: Flivo Press, SA; 2001.  Back to cited text no. 39
    
40.
Chua NH, Vissers KC, Sluijter ME. Pulsed radiofrequency treatment in interventional pain management: Mechanisms and potential indications-A review. Acta Neurochir (Wien) 2011;153:763-71.  Back to cited text no. 40
    
41.
Vanelderen P, Rouwette T, De Vooght P, Puylaert M, Heylen R, Vissers K, et al. Pulsed radiofrequency for the treatment of occipital neuralgia: A prospective study with 6 months of follow-up. Reg Anesth Pain Med 2010;35:148-51.  Back to cited text no. 41
    
42.
Cohen SP, Peterlin BL, Fulton L, Neely ET, Kurihara C, Gupta A, et al. Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness. Pain 2015;156:2585-94.  Back to cited text no. 42
    
43.
Stogicza A, Trescot A, Rabago D. New technique for cryoneuroablation of the proximal greater occipital nerve. Pain Pract 2019;19:594-601.  Back to cited text no. 43
    
44.
Kim CH, Hu W, Gao J, Dragan K, Whealton T, Julian C. Cryoablation for the treatment of occipital neuralgia. Pain Physician 2015;18:E363-8.  Back to cited text no. 44
    
45.
Trescot AM. Cryoanalgesia in interventional pain management. Pain Physician 2003;6:345-60.  Back to cited text no. 45
    
46.
Myers RR, Powell HC, Heckman HM, Costello ML, Katz J. Biophysical and pathological effects of cryogenic nerve lesion. Ann Neurol 1981;10:478-85.  Back to cited text no. 46
    
47.
Loukas M, El-Sedfy A, Tubbs RS, Louis RG Jr, Wartmann CH, Curry B, et al. Identification of greater occipital nerve landmarks for the treatment of occipital neuralgia. Folia Morphol (Warsz) 2006;65:337-42.  Back to cited text no. 47
    
48.
Greher M, Moriggl B, Curatolo M, Kirchmair L, Eichenberger U. Sonographic visualization and ultrasound-guided blockade of the greater occipital nerve: A comparison of two selective techniques confirmed by anatomical dissection. Br J Anaesth 2010;104:637-42.  Back to cited text no. 48
    
49.
Kastler A, Attyé A, Maindet C, Nicot B, Gay E, Kastler B, et al. Greater occipital nerve cryoneurolysis in the management of intractable occipital neuralgia. J Neuroradiol 2018;45:386-90.  Back to cited text no. 49
    
50.
Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. Chronic effects of implanted devices. Appl Neurophysiol 1977;40:223-34.  Back to cited text no. 50
    
51.
Sakharpe AK, Cascella M. Occipital Nerve Stimulation. StatPearls [Internet]: StatPearls Publishing; 2020.  Back to cited text no. 51
    
52.
Goadsby PJ, Bartsch T, Dodick DW. Occipital nerve stimulation for headache: Mechanisms and efficacy. Headache 2008;48:313-8.  Back to cited text no. 52
    
53.
Deer TR, Mekhail N, Petersen E, Krames E, Staats P, Pope J, et al. The appropriate use of neurostimulation: Stimulation of the intracranial and extracranial space and head for chronic pain. Neuromodulation Appropriateness Consensus Committee. Neuromodulation 2014;17:551-70; discussion 70.  Back to cited text no. 53
    
54.
Trentman TL, Zimmerman RS. Occipital nerve stimulation: Technical and surgical aspects of implantation. Headache 2008;48:319-27.  Back to cited text no. 54
    
55.
Johnstone CS, Sundaraj R. Occipital nerve stimulation for the treatment of occipital neuralgia-eight case studies. Neuromodulation 2006;9:41-7.  Back to cited text no. 55
    
56.
Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia 2007;27:153-7.  Back to cited text no. 56
    
57.
Slavin KV, Nersesyan H, Wess C. Peripheral neurostimulation for treatment of intractable occipital neuralgia. Neurosurgery 2006;58:112-9; discussion -9.  Back to cited text no. 57
    
58.
Nico D, Daprati E, Rigal F, Parsons L, Sirigu A. Left and right hand recognition in upper limb amputees. Brain 2004;127:120-32.  Back to cited text no. 58
    
59.
Salmasi V, Olatoye OO, Terkawi AS, Hah JM, Ottestad E, Pingree M. Peripheral nerve stimulation for occipital neuralgia. Pain Med 2020;21(Suppl 1):S13-s7.  Back to cited text no. 59
    
60.
Bogduk N. The anatomy of occipital neuralgia. Clin Exp Neurol 1980;17:167-84.  Back to cited text no. 60
    
61.
Lozano AM, Vanderlinden G, Bachoo R, Rothbart P. Microsurgical C-2 ganglionectomy for chronic intractable occipital pain. J Neurosurg 1998;89:359-65.  Back to cited text no. 61
    
62.
Keith WS. “Whiplash”-injury of the 2nd cervical ganglion and nerve. Can J Neurol Sci 1986;13:133-7.  Back to cited text no. 62
    
63.
Acar F, Miller J, Golshani KJ, Israel ZH, McCartney S, Burchiel KJ. Pain relief after cervical ganglionectomy (C2 and C3) for the treatment of medically intractable occipital neuralgia. Stereotact Funct Neurosurg 2008;86:106-12.  Back to cited text no. 63
    
64.
Gfrerer L, Austen WG Jr, Janis JE. Migraine surgery. Plast Reconstr Surg Glob Open 2019;7:e2291.  Back to cited text no. 64
    
65.
Olesen J. International classification of headache disorders. Lancet Neurol 2018;17:396-7.  Back to cited text no. 65
    
66.
Amirlak B, Chung M, Kislevitz ML. Amirlak Modification of Site 4 Decompression: Endoscopic Assisted Decompression of the Greater Occipital Nerve (GON) with Radical Excision of the Occipital Artery. Atlas of Surgical Therapy for Migraine and Tension-Type Headache. Springer; 2020. p. 129-38.  Back to cited text no. 66
    
67.
Janis JE, Hatef DA, Ducic I, Reece EM, Hamawy AH, Becker S, et al. The anatomy of the greater occipital nerve: Part II. Compression point topography. Plast Reconstr Surg 2010;126:1563-72.  Back to cited text no. 67
    
68.
Guyuron B. Migraine Surgery: Thieme; 2018.  Back to cited text no. 68
    
69.
Amirlak B, Lu K, Chung M, Sanniec K. Endoscopic-assisted decompression of the greater occipital nerve for treatment of migraines and chronic headaches. in press. 2020.  Back to cited text no. 69
    
70.
Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. Neurol Sci 2015;36(Suppl 1):29-32.  Back to cited text no. 70
    
71.
Ducic I, Felder JM 3rd, Khan N, Youn S. Greater occipital nerve excision for occipital neuralgia refractory to nerve decompression. Ann Plast Surg 2014;72:184-7.  Back to cited text no. 71
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow